Who are VCT220 Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Repatha, Repatha®, LEQVIO, Evolocumab combined with statins, Evolocumab Prefilled Syringe, Praluent (Alirocumab).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vct220-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

VCT220 Tablet — Competitive Intelligence Brief

VCT220 Tablet (VCT220 Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PCSK9 inhibitor. Area: Cardiovascular.

phase 3 PCSK9 inhibitor PCSK9 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

VCT220 Tablet (VCT220 Tablet) — Vincentage Pharma Co., Ltd. VCT220 Tablet is a small molecule that targets the PCSK9 protein to lower LDL cholesterol.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
VCT220 Tablet TARGET	VCT220 Tablet	Vincentage Pharma Co., Ltd	phase 3	PCSK9 inhibitor	PCSK9
Repatha	EVOLOCUMAB	Repatha	marketed	PCSK9 Inhibitor [EPC]	PCSK9	2015-01-01
Repatha®	Repatha®	Sejong General Hospital	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)
LEQVIO	LEQVIO	University of Louisville	marketed	PCSK9 inhibitor (siRNA)	PCSK9 mRNA
Evolocumab combined with statins	Evolocumab combined with statins	Zibo Central Hospital	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9
Evolocumab Prefilled Syringe	Evolocumab Prefilled Syringe	University of Erlangen-Nürnberg Medical School	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9
Praluent (Alirocumab)	Praluent (Alirocumab)	Federico II University	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PCSK9 inhibitor class)

Amgen · 4 drugs in this class
Bayer · 2 drugs in this class
Allergan · 2 drugs in this class
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 drug in this class
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · 1 drug in this class
Hospital General Universitario Gregorio Marañon · 1 drug in this class
Novartis · 1 drug in this class
Shire · 1 drug in this class
Vincentage Pharma Co., Ltd · 1 drug in this class
Wolfson Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VCT220 Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/vct220-tablet. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab